

# We are targeting a possible cause of Huntington's disease

Please take a flyer for more information about the GENERATION HD2 study

## Why are we running GENERATION HD2?

Huntington's disease (HD) symptoms are caused by the build-up of a protein called mutant huntingtin (mHTT) in the fluid surrounding the brain and spinal cord. Today's treatments aim to reduce the symptoms caused by mHTT, rather than target the cause of mHTT itself. That's why we're conducting GENERATION HD2 – a study evaluating an investigational drug designed to target mHTT.

# Who are we looking for?

For this study we're looking for approximately 360 people who:

- ◆ Are between 25 and 50 years old (at the start of the study)
- ◆ Have a CAP score of 400 to 500. A CAP score is a number which is calculated to provide a measurement of your HD progression. The study team can provide more information about this measure if you have not come across it before
- ◆ Have a formal diagnosis of early Huntingtons disease or who carry the abnormal huntingtin gene and are starting to show very early, subtle signs of HD, which may only be apparent during a detailed examination by a physician

# What will the study involve?

If you take part in GENERATION HD2, you will be involved for a minimum of 22 months. This will include up to 1 month of screening, a minimum of 16 months in the treatment period (where you will receive either the investigational drug or placebo), and one follow-up appointment 5 months after the treatment period ends. You will need to come into the clinic approximately once every 4 months and you will also receive a telephone call in-between each clinic visit so that we can monitor your health.

To take part in the study, you will need a study companion to support you through GENERATION HD2. Your study companion will need to attend clinic visits with you in-person for screening, at the start of your treatment period and in month 16 (or if you leave the study early) and be available for telephone calls at other timepoints during the study.

If the main study is successful, you may also be able to take part in an extension study where all participants will receive the investigational drug.

Please note that participation is entirely voluntary, and you can leave at any time without affecting your usual healthcare.

**To find out if you can join, or for more information, please speak to your doctor today or contact a member of the study team using the details below:**

Randy Foli  
email: [randy.foli@neurology.ufl.edu](mailto:randy.foli@neurology.ufl.edu)  
phone: 352-733-2433  
UF Health Fixel Institute for Neurological  
Diseases, 3009 SW Williston Rd  
Gainesville, FL 32608